Literature DB >> 3932356

The effect of glycoprotein-processing inhibitors on fucosylation of glycoproteins.

P M Schwarz, A D Elbein.   

Abstract

The influenza viral hemagglutinin contains L-fucose linked alpha 1,6 to some of the innermost GlcNAc residues of the complex oligosaccharides. In order to determine what structural features of the oligosaccharide were required for fucosylation or where in the processing pathway fucosylation occurred, influenza virus-infected MDCK cells were incubated in the presence of various inhibitors of glycoprotein processing to stop trimming at different points. After several hours of incubation with the inhibitors, [5,6-3H]fucose and [1-14C]mannose were added to label the glycoproteins, and cells were incubated in inhibitor and isotope for about 40 h to produce mature virus. Glycopeptides were prepared from the viral and the cellular glycoproteins, and these glycopeptides were isolated by gel filtration on Bio-Gel P-4. The glycopeptides were then digested with endo-beta-N-acetylglucosaminidase H and rechromatographed on the Bio-Gel column. In the presence of castanospermine or 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidine, both inhibitors of glucosidase I, most of the radioactive mannose was found in Glc3Man7-9GlcNAc structures, and these did not contain radioactive fucose. In the presence of deoxymannojirimycin, an inhibitor of mannosidase I, most of the [14C]mannose was in a Man9GlcNAc structure which was also not fucosylated. However, in the presence of swainsonine, an inhibitor of mannosidase II, the [14C]mannose was mostly in hybrid types of oligosaccharides, and these structures also contained radioactive fucose. Treatment of the hybrid structures with endoglucosaminidase H released the [3H]fucose as a small peptide (Fuc-GlcNAc-peptide), whereas the [14C]mannose remained with the oligosaccharide. The data support the conclusion that the addition of fucose linked alpha 1,6 to the asparagine-linked GlcNAc is dependent upon the presence of a beta 1,2-GlcNAc residue on the alpha 1,3-mannose branch of the core structure.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932356

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Mannose analog 1-deoxymannojirimycin inhibits the Golgi-mediated processing of bean storage glycoproteins.

Authors:  A Vitale; M Zoppè; R Bollini
Journal:  Plant Physiol       Date:  1989-04       Impact factor: 8.340

2.  Aminosugar derivatives as potential anti-human immunodeficiency virus agents.

Authors:  A Karpas; G W Fleet; R A Dwek; S Petursson; S K Namgoong; N G Ramsden; G S Jacob; T W Rademacher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

3.  Sulfate metabolism of rat P0 glycoprotein: some observations.

Authors:  M E Smith
Journal:  Neurochem Res       Date:  1994-08       Impact factor: 3.996

Review 4.  Iminosugars: Promising therapeutics for influenza infection.

Authors:  Beatrice Ellen Tyrrell; Andrew Cameron Sayce; Kelly Lyn Warfield; Joanna Louise Miller; Nicole Zitzmann
Journal:  Crit Rev Microbiol       Date:  2016-12-08       Impact factor: 7.624

Review 5.  Inhibitors of protein glycosylation and glycoprotein processing in viral systems.

Authors:  R Datema; S Olofsson; P A Romero
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

6.  N-glycosylation of colorectal cancer tissues: a liquid chromatography and mass spectrometry-based investigation.

Authors:  Crina I A Balog; Kathrin Stavenhagen; Wesley L J Fung; Carolien A Koeleman; Liam A McDonnell; Aswin Verhoeven; Wilma E Mesker; Rob A E M Tollenaar; André M Deelder; Manfred Wuhrer
Journal:  Mol Cell Proteomics       Date:  2012-05-09       Impact factor: 5.911

7.  Lysosomal delivery of the major myelin glycoprotein in the absence of myelin assembly: posttranslational regulation of the level of expression by Schwann cells.

Authors:  K R Brunden; J F Poduslo
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.